Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$49.19
$1.78(3.62%)
At close: 4:00 PM EDT
$49.19
$1.78(3.62%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume140.99K
Average Volume (3M)998.72K
Market Cap
$1.77B
Enterprise Value$999.46
Total Cash (Recent Filing)$320.68M
Total Debt (Recent Filing)$29.09M
Price to Earnings (P/E)13.4
Beta0.85
Next Earnings
Nov 09, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.66
Shares Outstanding28,910,376
10 Day Avg. Volume718,491
30 Day Avg. Volume998,719
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$60.15Price Target Upside22.29% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)0.91
Revenue Forecast (FY)$843.39M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong LiquidityMinimal leverage and substantial liquidity give Inspire flexibility to fund clinical, commercial and manufacturing initiatives while absorbing reimbursement disruption without relying heavily on external financing.
Clinical Evidence Supports Product DifferentiationPositive clinical evidence can strengthen physician confidence, patient adoption and payer discussions. Demonstrated benefits versus CPAP support Inspire’s differentiated position in the implantable OSA treatment market.
Project Horizon Creates Reinvestment CapacityOperational streamlining and supply-chain optimization could redirect resources toward patient access, education and procedure flow. If executed well, the plan may improve scalability and support renewed volume growth.
Bears Say
Reimbursement And Coding DisruptionUneven coding rules, authorization processes and WISeR uncertainty can delay procedures and complicate center planning. Persistent reimbursement friction may restrain adoption and make revenue recovery dependent on policy clarity.
Revenue Growth And Operating Leverage Have WeakenedRecent contraction indicates that reimbursement disruption is affecting procedure volumes and fixed-cost absorption. Continued weaker sales could limit operating leverage, slow investment returns and delay restoration of historical growth.
Restructuring And Reported Earnings VolatilityRestructuring charges and an unusually high effective tax rate can materially distort GAAP earnings and reduce near-term visibility. They also signal execution and transition costs as the company reallocates resources.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is $1.77B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Nov 09, 2026 which is in 78 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on Aug 03, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.236 by $0.376.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Undervalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is 0.08.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,910,376 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.236. Following the earnings report the stock price went up 22.827%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$60.15 (22.29% Upside)
$60.15 (22.29% Upside)
Blogger Sentiment
Bullish
INSP Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Company Deck
INSP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.View all INSP earnings summariesINSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$60.15
▲(22.29% Upside)
Technical Analysis
Ownership Overview
1.70% Insiders
28.63% Mutual Funds
27.36% Other Institutional Investors
14.60% Public Companies and
Individual Investors